AstraZeneca Recalls Samples of Brilinta
The company voluntarily recalled one lot of Brilinta 90 mg professional samples because it contained another medicine.
On May 24, 2017, AstraZeneca announced it was voluntarily recalling one lot of professional sample bottles of Brilinta 90 mg tablets distributed to physicians in the United States between March and April 2017. The nationwide recall is due to a report that one sample bottle contained Brilinta and Zurampic 200 mg tablets. Zurampic is also manufactured by AstraZeneca.
The company stated in a press release that the recall was precautionary and other forms and dosage strengths of Brilinta or Zurampic were not affected by the recall. As of the May 24, the company had not received any reports of adverse events. According to the company, unintentional use of Zurampic, which is used to treat gout, could lead to adverse renal effects. Brilinta is used to treat acute coronary syndrome and other heart conditions.
Source: FDA
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
